Blood products and parvovirus BI9

Netherlands Journal of Medicine

Volumn 61, Issue 5, 2003, Pages 154-156

  Groeneveld, K ^a   van der Noordaa, J ^b  

^a Health Council of the Netherlands   (Netherlands)

^b Department of Virology ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ADVISORY COMMITTEE; ANTIBODY DETECTION; APHERESIS; BLOOD ANALYSIS; BLOOD COMPONENT; BLOOD DONOR; BLOOD SAMPLING; DISEASE COURSE; DISEASE SEVERITY; DOT HYBRIDIZATION; ERYTHEMA INFECTIOSUM; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; NANOFILTRATION; NETHERLANDS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PARVOVIRUS; PLASMA; PREGNANCY; REVIEW; RISK ASSESSMENT; SAFETY; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS INFECTIVITY;

BLOOD; BLOOD DONORS; HUMANS; PARVOVIRUS B19, HUMAN;

EID: 3042674482     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Elsacker-Niele AMW van, Kroes ACM. Human Parvovirus B19: relevance in internal medicine. Neth J Med 1999;54:221-30.
2. Cherry JD. Parvovirus Infections in children and adults. In: Advances in pediatrics. Mosby Inc: 1999:245-69.
3. AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997;127:904-9.
4. Kleinman SH, Glynn SA, Busch MP, Wright DJ, McMullen Q, Schreiber GB. Declining incidence rates and risks of transfusion-transmitted viral infections in US blood donors. Vox Sang 2002;83:106.
5. Health Council of the Netherlands. Blood products and Parvovirus B19. The Hague: Health Council of the Netherlands, 2002; publication no. 2002/07E, www.healthcouncil.nl.
6. Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of Parvovirus B19. Trans Med Rev 1999;13:194-204.
7. Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989;84:1114-23.
8. Public Health Laboratory Service working party on fifth disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 1990;300:1166-70.
9. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998;105:174-8.
10. Tolfvenstam T, Papadogiannakis N, Norbeck O, Petersson K, Broliden K. Frequency of human parvovirus B19 in intrauterine fetal death. Lancet 2001;357:1494-7.
11. Luban NLC. Human parvoviruses: implications for transfusion medicine. Transfusion 1994;34:821-7.
12. Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997;53:229-32.
13. Lundqvist A, Tolfvenstam T, Bostic J, Söderlund M, Broliden K. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis 1999;31:11-6.
14. Söderlund M, Essen RV, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997;349:1063-5.
15. Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JAJ. Blood donor screening for Parvovirus B19. J Virol Meth 1990;30:233-8.
16. Jordan J, Tiangco B, Kiss J, Koch W. Human Parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang 1998;75:97-102.
17. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993;31:323-8.
18. Tsujimura M, Matsushita K, Shiraki H, Sato H, Okochi K, Maede Y. Human parvovirus B19 infections in blood donors. Vox Sang 1995;69:206-12.
19. Yoto Y, Kudoh T, Haseyama K. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995;91:1017-8.
20. Willkommen H, Schmidt I, Löwer J. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals 1999;27:325-31.
21. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996;93:714-9.
22. Brown KE, Young NS, Barbosa LH. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001;41:130-5.
23. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 2000;40:84-90.
24. Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang 2000;78:205-10.
25. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994;67:132-8.